Active prescription of low-dose aspirin during or prior to hospitalization and mortality in COVID-19: A systematic review and meta-analysis of adjusted effect estimates - ScienceDirect
Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection - The American Journal of Medicine
Use of non-steroidal anti-inflammatory drugs and adverse outcomes during the COVID-19 pandemic: A systematic review and meta-analysis - eClinicalMedicine
Methods and Protocols in COVID-19 Research, Diagnostic and Treatment | Biology Methods and Protocols | Oxford Academic
Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents - The Lancet Infectious Diseases
Association of mortality and aspirin use for COVID-19 residents at VA Community Living Center Nursing Homes | medRxiv
Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico - International Journal of Infectious Diseases
Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia - The Lancet Respiratory Medicine
Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation | Nature Reviews Cardiology
Aspirin | C9H8O4 | CID 2244 - PubChem
Frontiers | Aspirin in COVID-19: Pros and Cons
Full article: Low-dose aspirin for early COVID-19: does the early bird catch the worm?
COVID-19 therapeutics: Challenges and directions for the future | PNAS
Frontiers | Aspirin in COVID-19: Pros and Cons
Aspirin may reduce risk of severe COVID symptoms: Study
Does aspirin have an effect on risk of death in patients with COVID-19? A meta-analysis | SpringerLink
Neurology International | Free Full-Text | Ischemic Stroke and SARS-CoV-2 Infection: The Bidirectional Pathology and Risk Morbidities
Therapeutic advances in COVID-19 | Nature Reviews Nephrology
Medicina | Free Full-Text | Aspirin Is Related to Worse Clinical Outcomes of COVID-19
Full article: Low-dose aspirin for early COVID-19: does the early bird catch the worm?
Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial - The Lancet Respiratory Medicine
Frontiers | Long COVID: The Nature of Thrombotic Sequelae Determines the Necessity of Early Anticoagulation
Frontiers | Aspirin Bioactivity for Prevention of Cardiovascular Injury in COVID-19
A guide to immunotherapy for COVID-19 | Nature Medicine
Aspirin & COVID-19 | The International Aspirin Foundation
Biomedicines | Free Full-Text | Aspirin and Infection: A Narrative Review
To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial - British Journal of Anaesthesia
Aspirin Therapy on Prophylactic Anticoagulation for Patients Hospitalized With COVID‐19: A Propensity Score‐Matched Cohort Analysis of the HOPE‐COVID‐19 Registry | Journal of the American Heart Association
